- Conditions
- Rett Syndrome
- Interventions
- Trofinetide
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 5 Years to 21 Years · Female only
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Barretts Esophagus With Dysplasia, Barrett Esophagus, Esophageal Adenocarcinoma
- Interventions
- Endoscopic Eradication Therapy
- Procedure
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 25 more
- Conditions
- Major Depressive Disorder
- Interventions
- DVS SR
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 283 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Imperial, California + 28 more
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- cirmtuzumab
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Metastatic Breast Cancer
- Interventions
- Exemestane, Sutent
- Drug
- Lead sponsor
- Baylor Breast Care Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma, Giant Lymph Node Hyperplasia
- Interventions
- CNTO 328
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Tampa, Florida • Atlanta, Georgia + 6 more
- Conditions
- Hematological Malignancies
- Interventions
- Talquetamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 10 more
- Conditions
- Chronic Migraine, Migraine Disorders, Headache Disorders, Headache, Migraine
- Interventions
- Osteopathic Manipulative Therapy (OMT), Standard of care
- Procedure · Other
- Lead sponsor
- St. Luke's Hospital, Pennsylvania
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Bethlehem, Pennsylvania
- Conditions
- Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder
- Interventions
- BPN14770, Placebo
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 9 Years to 45 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Seattle, Washington
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- eteplirsen
- Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 7 Years to 16 Years · Male only
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 32 more
- Conditions
- Sickle Cell Disease
- Interventions
- Music therapy, Health education
- Behavioral · Other
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Greenville, South Carolina
- Conditions
- Intraocular Melanoma, Melanoma (Skin)
- Interventions
- MART-1 antigen, gp100:209-217(210M) peptide vaccine, therapeutic autologous dendritic cells, tyrosinase peptide
- Biological
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Ann Arbor, Michigan
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Ketamine, Exposure and Response Prevention
- Drug · Behavioral
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer Disease
- Interventions
- AR1001, Placebo
- Drug
- Lead sponsor
- AriBio Co., Ltd.
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 1,535 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 75
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 62 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Spesolimab 1200 mg, Spesolimab 600 mg, Placebo matching 600 mg Spesolimab, Placebo matching 1200 mg Spesolimab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Indianapolis, Indiana • Rochester, Minnesota + 1 more
- Conditions
- Osteoarthritis of Knee, Edema, Wounds and Injuries
- Interventions
- ODIN1, Standard Care, Diagnostic Device Testing
- Device · Other
- Lead sponsor
- Bioelectric Research Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 2
- States / cities
- Las Vegas, Nevada
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Disease, Hypertension, Inadequate Glycaemic Control
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 922 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 60
- States / cities
- Gulf Shores, Alabama • Phoenix, Arizona • Burbank, California + 57 more
- Conditions
- Respiratory Failure, ARDS
- Interventions
- Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)
- Device
- Lead sponsor
- Marker Therapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 7
- States / cities
- Little Rock, Arkansas • Albuquerque, New Mexico • Portland, Oregon + 4 more
- Conditions
- Epilepsies, Partial
- Interventions
- ganaxolone
- Drug
- Lead sponsor
- Marinus Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
- Conditions
- Focal Onset Seizures
- Interventions
- JNJ-40411813, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 7
- States / cities
- Tucson, Arizona • Orlando, Florida • Port Orange, Florida + 4 more
- Conditions
- Crohn's Disease
- Interventions
- PF-04236921
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 62
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Lakewood, Colorado + 30 more
- Conditions
- Alzheimer Disease
- Interventions
- lecozotan SR (SRA-333)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 30 more
- Conditions
- Liver Tumor
- Interventions
- RFA controlled using echo decorrelation imaging, RFA controlled using standard manufacturer-specified algorithms
- Procedure
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Achondroplasia
- Interventions
- Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 0 Years to 32 Months
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 3
- States / cities
- Oakland, California • Baltimore, Maryland • Madison, Wisconsin